132 related articles for article (PubMed ID: 38561282)
1. [Analysis of the factors influencing the severity of coronavirus disease 2019 in patients with myeloproliferative neoplasms based on an online questionnaire].
Qi FY; Bao M; Gao HL; Jiang Q
Zhonghua Nei Ke Za Zhi; 2024 Apr; 63(4):371-377. PubMed ID: 38561282
[No Abstract] [Full Text] [Related]
2. Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Patients with Philadelphia-Negative Myeloproliferative Neoplasm: A Single Center Experience.
Ali EAH; Khamees I; Alshurafa A; Qasim H; Abu-Tineh MA; Ahmed K; Saad E; Yassin M
Oncology; 2022; 100(8):460-466. PubMed ID: 35882185
[TBL] [Abstract][Full Text] [Related]
3. [Clinical and genetic characteristics of young patients with myeloproliferative neoplasms].
Zhang MY; Bao M; Shi DY; Shi HX; Liu XL; Xu N; Duan MH; Zhuang JL; Du X; Qin L; Hui WH; Liang R; Wang MF; Chen Y; Li DY; Yang W; Tang GS; Zhang WH; Kuang X; Su W; Han YQ; Chen LM; Xu JH; Liu ZG; Huang J; Zhao CT; Tong HY; Hu JD; Chen CY; Chen XQ; Xiao ZJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):193-201. PubMed ID: 37356980
[No Abstract] [Full Text] [Related]
4. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
Mesa R; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Boyle J; Mascarenhas JO
BMC Cancer; 2016 Feb; 16():167. PubMed ID: 26922064
[TBL] [Abstract][Full Text] [Related]
5. [Health-related quality of life and its associated variables in Chinese patients with Philadelphia-negative myeloproliferative neoplasms].
Bao M; Shi DY; Shi HX; Liu XL; Duan MH; Zhuang JL; Du X; Qin L; Hui WH; Liang R; Wang MF; Chen Y; Li DY; Yang W; Tang GS; Zhang WH; Kuang X; Su W; Han YQ; Chen LM; Xu JH; Liu ZG; Huang J; Zhao CT; Tong HY; Hu JD; Chen CY; Chen XQ; Xiao ZJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):985-992. PubMed ID: 35045668
[No Abstract] [Full Text] [Related]
6. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
7. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
Mesa RA; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Naim A; Parasuraman S; Boyle J; Mascarenhas JO
Cancer; 2017 Feb; 123(3):449-458. PubMed ID: 27690182
[TBL] [Abstract][Full Text] [Related]
8. Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain.
Ortuzar A; Fox ML; Vera JA; Lorenzo Vizcaya Á; Marín Sánchez A; Llopis Calatayud I; Carbonell S; Álvarez-Larrán A; Mata Serna R; Marco Buades JE; Quiroz Cervantes K; Martínez Hellín Á; Blum Domínguez A; Caballero Navarro G; Cáceres Sansaloni A; Guerrero Fernández L; Muñoz Linares C; Gasior Kabat M; Pérez López R; Fernández Rodríguez Á; Martínez Bilbao C; Cobo Rodríguez MT; Díaz Á; Durán MA; Santaliestra Tomas M; García-Gutierrez V; Magro Mazo E; Hernández-Boluda JC; Segura A; Raya JM; Navas Elorza B; Osorio S
Ann Hematol; 2023 Feb; 102(2):447-456. PubMed ID: 36422672
[TBL] [Abstract][Full Text] [Related]
9. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
[TBL] [Abstract][Full Text] [Related]
10. Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey.
Yu J; Parasuraman S; Paranagama D; Bai A; Naim A; Dubinski D; Mesa R
BMC Cancer; 2018 Apr; 18(1):420. PubMed ID: 29653557
[TBL] [Abstract][Full Text] [Related]
11. Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms.
Shi D; Shi H; Liu X; Duan M; Zhuang J; Du X; Qin L; Hui W; Liang R; Wang M; Chen Y; Li D; Yang W; Tang G; Zhang W; Kuang X; Su W; Han Y; Chen L; Xu J; Liu Z; Huang J; Zhao C; Tong H; Hu J; Chen C; Chen X; Xiao Z; Jiang Q
Leuk Lymphoma; 2021 Nov; 62(11):2703-2715. PubMed ID: 34098836
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of frailty and its association with clinical outcomes in myeloproliferative neoplasms: a population-based study.
Bankar A; Chan WC; Liu N; Cheung M; Alibhai S; Gupta V
Blood Adv; 2023 Sep; 7(17):5014-5026. PubMed ID: 37184988
[TBL] [Abstract][Full Text] [Related]
13. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
14. Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
Baumeister J; Chatain N; Sofias AM; Lammers T; Koschmieder S
Cells; 2021 Dec; 10(12):. PubMed ID: 34944059
[TBL] [Abstract][Full Text] [Related]
15. Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study.
Larsen MK; Skov V; Kjær L; Eickhardt-Dalbøge CS; Knudsen TA; Kristiansen MH; Sørensen AL; Wienecke T; Andersen M; Ottesen JT; Gudmand-Høyer J; Snyder JA; Andersen MP; Torp-Pedersen C; Poulsen HE; Stiehl T; Hasselbalch HC; Ellervik C
Blood Cancer J; 2024 Feb; 14(1):28. PubMed ID: 38331919
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany.
Schmidt A; Bernhardt C; Bürkle D; Fries S; Hannig CV; Jentsch-Ullrich K; Josting A; Kreher S; Reiser M; Steinmetz HT; Tesch H; Terner S; Schulte A; Crodel CC; Palandri F; Heidel FH
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7197-7206. PubMed ID: 36884118
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of prognostic factors in Chinese patients with post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis].
Chen M; Xu ZF; Xu JQ; Li B; Zhang PH; Qin TJ; Zhang Y; Wang JY; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):876-880. PubMed ID: 27801320
[TBL] [Abstract][Full Text] [Related]
18. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
[TBL] [Abstract][Full Text] [Related]
19. Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN).
Price GL; Davis KL; Karve S; Pohl G; Walgren RA
PLoS One; 2014; 9(3):e90299. PubMed ID: 24618579
[TBL] [Abstract][Full Text] [Related]
20. Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea.
Lim Y; Lee JO; Bang SM
J Korean Med Sci; 2016 Oct; 31(10):1579-85. PubMed ID: 27550486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
